Arterial hypertension in young people and adolescents: diagnostics and treatment
Abstract
The current evidence on causes, diagnostics and treatment of arterial hypertension (AH) in adolescents and young people is presented. AH features in these age groups, angiotensin receptor blocker potential in prevention of AH stabilisation, as well as early prevention of cardiovascular events are discussed. The authors present their original data on the prevalence oflabile AH, autonomous dysfunction, metabolic syndrome, abdominal obesity, and hyperleptinemia in adolescents with AH.
About the Authors
O. A. Kislyak
Russian State Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
E. V. Petrova
Russian State Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
D. S. Sargaeva
Russian State Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Шальнова С.А. Эпидемиология артериальная гипертонии. В кн. Руководство по артериальной гипертензии. Под редакцией Е.И.Чазова и И.Е.Чазовой. Москва “Медиа Медика” 2005; 79-95.
2. The Fourth Report on the Diagnosis, Evaluation, and Treatment of Higli Blood Pressure in Children and Adolescents. Pediatrics 2004; (114 Supplement): 555—76.
3. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23: 528-35. '
4. Петрова E.B. Состояние сердечно-сосудистой системы у подростков и лиц молодого возраста с ожирением и другими метаболическими факторами риска. Автореферат дис канд мед наук. Москва 2008.
5. Розанов В.Б. Прогностическое значение факторов риска сердечно-сосудистых заболеваний, связанных с атеросклерозом, у детей и подростков и отдаленные результаты профилактического вмешательства. Автореф дис докт мед наук. Москва 2007.
6. Freedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998; 56(2 Pt 2): S38-46.
7. Magalhaes MEC, Pozzan R, Brandao AA, et al. Early blood pressure level as a mark of f amilial aggregation of metabolic cardiovascular risk factors — the Rio de Janeiro study. J Hypertens 1998; 16: 1885-9.
8. Петрова E.B., Сторожаков Е.И., Кисляк O.A. Толщина комплекса интима-медиа у подростков и лиц молодого возраста. Росс нац конгр кардиологов. Материалы конгресса. Москва 2005; 256—7.
9. Unger Т. Blood pressure lowering and renin angiotensin system blockade. J Hypertens 2003; 21(Su pi. 6): S3—7.
10. Диагностика и лечение артериальной гипертензии. Рекомендации ВНОК. Приложение 2 к ж “Кардиоваск. тер. профил.” 2008; 7: 31 с.
11. Julius S, Nessbitt SD, Egan BM, et al. Feasibility of treating prehypertension with the angiotensin-receptor blocker (TROPHY). N EnglJ Med 2006; 354-7.
12. Malmqvist K, Kalian T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-76.
13. Диагностика и лечение метаболического синдрома. Российские рекомендации ВНОК. Приложение № 2 к ж “Кардиоваск. тер. профил.”. Москва 2007; 26 с.
14. Derosa G, Cicero AFG, D’Angelo A, et al. Telmisartan and Irbesartan in type 2 Diabetic patients treated with rosiglita-zone: effects on insulin-resistance, leptin and tumor necrosis factor a. Hypertens Res 2006; 29: 849-56.
Review
For citations:
Kislyak O.A., Petrova E.V., Sargaeva D.S. Arterial hypertension in young people and adolescents: diagnostics and treatment. Cardiovascular Therapy and Prevention. 2009;8(2):82-88. (In Russ.)
Views:
807
Email this article 
